Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Grifols International

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GIGA-2050

            Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050

            Highest Development Status: IND Enabling Product Type: Large molecule

            Recipient: GigaGen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 09, 2021

            Details:

            GIGA-2050 comprises more than 12,000 antibodies, encompassing a diverse set of anticoronavirus antibodies captured from the convalescent blood of 16 exceptional responders to COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GRF6021

            Therapeutic Area: Neurology Product Name: GRF6021

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Alkahest

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2021

            Details:

            In the phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints and was safe and well tolerated by study participants.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SARS-CoV-2 polyclonal antibodies

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2021

            Details:

            Grifols will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hyperimmune globulin

            Therapeutic Area: Infections and Infectious Diseases Product Name: ITAC

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            First international multicenter clinical trial of an anti-SARS-CoV-2 hyperimmune globulin and will include 500 hospitalized adults with COVID-19 in up to 58 hospitals in 18 countries. The therapy comes from the convalescent plasma of healthy people who have recovered COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Plasma-based therapies

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Alkahest

            Deal Size: $146.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 07, 2020

            Details:

            Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Perflutren,Immunoglobulin G 285-292

            Therapeutic Area: Neurology Product Name: Albutein

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fostamatinib Disodium

            Therapeutic Area: Immunology Product Name: Tavalisse

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Rigel Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            Details:

            TAVLESSE, which is marketed in the U.S. under the brand name TAVALISSE®, is an oral spleen tyrosine kinase (SYK) inhibitor that targets the underlying autoimmune cause of ITP by impeding platelet destruction.